Home > Resources > Whitepapers > DSM Looks to Challenge Traditional Stent Graft Materials with its Dyneema Purity® Membrane

DSM Looks to Challenge Traditional Stent Graft Materials with its Dyneema Purity® Membrane

October 17, 2017

A rising global demand for more minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases are driving the market to look for new and more efficient materials to construct stent grafts used in those procedures.Download this whitepaper to learn more about DSM and the benefits of using the Dyneema Purity membrane.

Spotlight

Microscopes International LLC

Microscopes International LLC is "The revolutionary new Digital Microscope Company". Our second generation digital microscope, the uScopeMXII, is a portable, low-cost device that is suitable for a wide variety of microscopy pursuits. It is great for remote viewing and telepathology.

OTHER WHITEPAPERS

Innovative strategies to maintain product integrity in Biologic andBiosimilar clinical studies

whitePaper | August 7, 2022

The number of biologic new molecular entities approved by the FDA has increased over the last five years indicates a growing focus on biosimilar.

Genetic insights for biopharmaceuticals: Propelling drug candidates into therapeutic assets

whitePaper | March 9, 2023

For biopharmaceutical and biotechnology companies, innovation is imperative. Economic growth in these industries relies heavily upon investment in product development—perhaps more so than any other industry

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

bFGF Supports Human ES Cell Self-Renewal

whitePaper | March 24, 2023

Basic fibroblast growth factor (bFGF) is an important cytokine used to support the growth and self renewal of human embryonic stem cells.

Long-term follow-up studies of cell and gene therapies

whitePaper | September 29, 2022

The market is experiencing a surge in the availability of cell and gene therapies (CGTs); it’s estimated that by 2025 as many as 20 will be introduced into the US each year.1,2

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.